On 25 November 2022, researchers at the Perelman School of Medicine at the University of Pennsylvania announced that initial tests showed effectiveness of a new mRNA-based flu vaccine. In the initial testing, a new mRNA vaccine that is touted to cover all 20 known strains of influenza, was injected into lab animals and showed antibody responses. The study, led by Dr Scott Hensley, was coordinated with Dr Drew Weissman, a physician researcher who helped bring the controversial COVID-19 mRNA vaccine to fruition and ultimately utilization globally.
The research team at University of Pennsylvania is hopeful that future human clinical trials will elicit a similar response. Their goal is to substitute the new mRNA for the current flu vaccines and target all age groups including young children.
This development is problematic on many levels. First, mRNA technology is new and the long-term effects are unknown. Pfizer tried to suppress reports of complications and deaths and was thwarted in early 2022 by a federal judge. In late 2022, Pfizer was forced to acknowledge that the vaccine causes problematic inflammation that can cause medical problems in the heart and other organs. They finally announced recently that they were conducting research into myocarditis from their mRNA vaccine.
Thanks! Share it with your friends!
Tweet
Share
Pin It
LinkedIn
Google+
Reddit
Tumblr